Skip To Main Content

Cell Therapies for Life-Threatening Diseases

The Unmet Needs

LyGenesis’s cell therapies are targeted at some of the largest unmet needs in medicine, from Type 1 diabetes to end stage liver and renal disease.


Our Pipeline

Small Animal
Large Animal
Phase 1
Phase 2
Phase 3
FDA Approval
  • Liver
    End Stage Liver Disease
    Phase 2A
  • Thymus
    POC Completed
  • Kidneys
    End Stage Renal Disease
    POC Completed
  • Pancreas
    Type 1 Diabetes
    POC Completed

LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs.

stock image of scientists in lab coats and gloves

Revolutionary Biotechnology

Our allogeneic cell therapies leverage the biology of the lymph node to engraft, proliferate, and form functional ectopic organs that recapitulate the native organ’s function.